8-10-2024, 13:35

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Globe Newswire8-10-2024, 13:35
7-06-2024, 15:30

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Globe Newswire7-06-2024, 15:30
26-02-2024, 14:05

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Globe Newswire26-02-2024, 14:05